

## AngioDynamics Announces Availability of Mariner™ Hydrophilic Angiographic Catheter

Queensbury, NY, May 12, 2004 – ANGIODYNAMICS, INC., a wholly owned subsidiary of E-Z-EM, Inc., (AMEX: EZM) today announced the release of the Mariner™ angiographic catheter, a hydrophilic-coated angiographic catheter designed to deliver contrast media to anatomy that is difficult to reach. With today's announcement, the Mariner catheter will be available in limited distribution within the United States and internationally.

The Mariner angiographic catheter features AngioDynamics' patented Soft-Vu® technology—an atraumatic Super-Radiopaque™ tip, which is highly visible under fluoroscopy combined with Duration™ coating technology. The Duration hydrophilic coating technology significantly reduces catheter surface friction, permitting smoother navigation through challenging vasculature with optimal handling and control.

Commenting for AngioDynamics, Michelle Mechaley, Director of Angiographic Products said, “The Mariner angiographic catheter represents the next step in catheter development. By combining our market leading Soft-Vu technology with a new hydrophilic coating, this product is designed to address physicians' needs for durability combined with smooth navigation, handling and control. The Mariner catheter demonstrates our ongoing commitment to the development of high quality catheters designed to advance the art and science of vascular procedures and patient care.”

For additional information on the Mariner angiographic catheter, contact Michelle Mechaley at 1-800-772-6446, ext. 341, Email: [mmechaley@angiodynamics.com](mailto:mmechaley@angiodynamics.com) or visit the AngioDynamics web site at [www.angiodynamics.com](http://www.angiodynamics.com).

### About AngioDynamics

AngioDynamics, Inc. ([www.angiodynamics.com](http://www.angiodynamics.com)) is a leading provider of innovative medical devices used in minimally invasive, image-guided procedures to treat peripheral vascular disease. AngioDynamics designs, develops, manufactures and markets a broad line of therapeutic and diagnostic devices that enable interventional physicians, such as interventional radiologists, vascular surgeons and others, to treat peripheral vascular diseases and other non-coronary diseases.

### About E-Z-EM

E-Z-EM is a leading manufacturer of contrast agents for gastrointestinal radiology. The Company has developed the only CT injector on the market that can help detect contrast extravasation, the EmpowerCT® with patented EDA™ technology; it also offers a complete product set for the virtual colonoscopy practitioner. This product line consists of virtual colonoscopy hardware, software, nutritional prep kits and bowel cleaners, tagging agents and a carbon dioxide colon insufflation system.

The statements made in this document contain certain forward looking statements that involve a number of risks and uncertainties. Words such as “expects”, “intends”, “anticipates”, “plans”, “believes”, “seeks”, “estimates,” or variations of such words and similar expressions, are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations. In addition to the matters described above, the ability of the Company to develop its products, market acceptance and future sales of the Mariner angiographic catheter, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from Group Purchasing Organizations, competition, including alternative procedures which continue to replace traditional fluoroscopic procedures, as well as the risk factors listed from time to time in the SEC filings of E-Z-EM, Inc., including but not limited to its Form 10-Q for the quarter ended February 28, 2004, as well as its Annual Report on Form 10-K for the year ended May 31, 2003, may affect the actual results achieved by the Company.

Company Contacts:  
AngioDynamics, Inc.  
Lisa Donegan  
(800) 772-6446 x370  
[www.angiodynamics.com](http://www.angiodynamics.com)

Investor Relations Contacts:  
Lippert/Heilshorn & Associates, Inc.

Kim Sutton Golodetz (kgolodetz@lhai.com)  
(212) 838-3777

Bruce Voss (bvoss@lhai.com)  
(310) 691-7100